Published in J Virol on September 01, 1991
Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A (1993) 9.47
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol (1994) 6.76
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A (1993) 6.14
Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A (1991) 5.83
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol (1994) 5.36
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother (1993) 4.96
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A (1995) 4.37
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol (1992) 3.46
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol (1994) 3.45
Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother (1994) 3.07
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 3.00
3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (1992) 2.97
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J Virol (1992) 2.85
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1994) 2.81
Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1994) 2.71
Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol (1995) 2.68
Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother (1993) 2.68
Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc Natl Acad Sci U S A (1994) 2.56
Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol (2010) 2.48
L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1995) 2.39
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol (1995) 2.24
Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1994) 2.24
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother (1995) 2.21
In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci U S A (1993) 2.16
A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A (1993) 2.15
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother (1996) 2.13
Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother (1993) 2.10
Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (1995) 2.04
Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci U S A (1991) 2.00
Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol (2004) 1.90
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 1.86
Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine. Proc Natl Acad Sci U S A (1993) 1.84
Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol (1994) 1.80
Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol (2003) 1.79
Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A (1993) 1.71
Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1. J Virol (2007) 1.71
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother (1993) 1.62
Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci U S A (1996) 1.58
Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc Natl Acad Sci U S A (1997) 1.55
Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother (1997) 1.53
Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob Agents Chemother (1994) 1.53
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
Mutational analysis of the fingers domain of human immunodeficiency virus type 1 reverse transcriptase. J Virol (1992) 1.48
U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (1993) 1.43
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother (2000) 1.42
Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol (1993) 1.41
Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1994) 1.40
Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations. J Am Chem Soc (2008) 1.39
Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother (1992) 1.39
Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother (2005) 1.38
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother (1995) 1.36
Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob Agents Chemother (1993) 1.35
In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob Agents Chemother (1993) 1.33
Hydroxyl radical footprint analysis of human immunodeficiency virus reverse transcriptase-template.primer complexes. Proc Natl Acad Sci U S A (1993) 1.32
Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide. Antimicrob Agents Chemother (1995) 1.31
Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 1.30
Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother (1998) 1.30
Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother (2009) 1.26
Mutagenesis of the Glu-89 residue in human immunodeficiency virus type 1 (HIV-1) and HIV-2 reverse transcriptases: effects on nucleoside analog resistance. J Virol (1992) 1.26
Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc Natl Acad Sci U S A (1993) 1.24
Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother (2005) 1.19
Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res (1995) 1.19
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1996) 1.16
Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother (1994) 1.15
2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc Natl Acad Sci U S A (1992) 1.14
Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proc Natl Acad Sci U S A (1993) 1.13
Mutagenicity and pausing of HIV reverse transcriptase during HIV plus-strand DNA synthesis. Nucleic Acids Res (1994) 1.13
In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine. Antimicrob Agents Chemother (1997) 1.12
Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants. Proc Natl Acad Sci U S A (1994) 1.10
Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines. Antimicrob Agents Chemother (1994) 1.08
Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob Agents Chemother (1994) 1.07
Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob Agents Chemother (1996) 1.05
Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection. Clin Microbiol Rev (1996) 1.02
Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob Agents Chemother (1993) 1.01
Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J Virol (1994) 1.00
The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2006) 1.00
Posttranscriptional modification of retroviral primers is required for late stages of DNA replication. Proc Natl Acad Sci U S A (1997) 0.99
Quantitative structure-activity relationship analysis of pyridinone HIV-1 reverse transcriptase inhibitors using the k nearest neighbor method and QSAR-based database mining. J Comput Aided Mol Des (2005) 0.99
Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. Biophys J (2003) 0.97
Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc Natl Acad Sci U S A (1996) 0.96
The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. Proc Natl Acad Sci U S A (1993) 0.95
[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1992) 0.95
Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661. Proc Natl Acad Sci U S A (1993) 0.94
In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother (2013) 0.93
Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase. Antimicrob Agents Chemother (1995) 0.92
Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives). Proc Natl Acad Sci U S A (1995) 0.92
Recombinant retroviral systems for the analysis of drug resistant HIV. Nucleic Acids Res (1993) 0.92
Antiretroviral therapy: reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.92
Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A (1998) 0.91
Michellamine B, a novel plant alkaloid, inhibits human immunodeficiency virus-induced cell killing by at least two distinct mechanisms. Antimicrob Agents Chemother (1995) 0.91
Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 0.90
Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase. J Virol (1994) 0.90
Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions. Antimicrob Agents Chemother (1994) 0.87
The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1995) 0.87
New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs. Antimicrob Agents Chemother (1994) 0.86
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science (1988) 220.77
A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology (1973) 127.36
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (1989) 15.19
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 14.63
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science (1988) 11.05
Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature (1981) 9.25
Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses (1987) 7.85
Finding sequence motifs in groups of functionally related proteins. Proc Natl Acad Sci U S A (1990) 7.65
Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol (1988) 6.76
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (1990) 5.70
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science (1990) 5.49
A sequence motif in many polymerases. Nucleic Acids Res (1988) 5.33
Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature (1987) 4.45
Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci U S A (1989) 4.15
Domain structure of the Moloney murine leukemia virus reverse transcriptase: mutational analysis and separate expression of the DNA polymerase and RNase H activities. Proc Natl Acad Sci U S A (1988) 3.02
Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci U S A (1991) 2.67
BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother (1991) 2.66
Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine. J Virol (1987) 2.33
Expression of enzymatically active reverse transcriptase in Escherichia coli. Proc Natl Acad Sci U S A (1985) 2.11
HIV-1 reverse transcriptase: structure predictions for the polymerase domain. AIDS Res Hum Retroviruses (1990) 1.80
Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol (1991) 1.79
Mutational analysis of the ribonuclease H activity of human immunodeficiency virus 1 reverse transcriptase. Virology (1990) 1.79
Effects of small insertions on the RNA-dependent DNA polymerase activity of HIV-1 reverse transcriptase. Virology (1989) 1.62
Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med (1991) 1.60
Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycins: competitive interaction at the template.primer site. Mol Pharmacol (1990) 1.30
Recombinant feline herpesviruses expressing feline leukemia virus envelope and gag proteins. J Virol (1990) 0.92
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature (1981) 16.61
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 10.13
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol (1985) 5.73
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (1992) 4.75
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Direct text entry in electronic progress notes. An evaluation of input errors. Methods Inf Med (2003) 4.00
Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol (1992) 3.85
Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry (2001) 3.84
Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides. Nature (1983) 3.35
Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci U S A (1994) 3.33
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol (1994) 3.33
Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C. J Virol (1986) 3.15
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med (1993) 2.98
Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature (1998) 2.90
Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol (1993) 2.89
Analysis of clock proteins in mouse SCN demonstrates phylogenetic divergence of the circadian clockwork and resetting mechanisms. Neuron (2000) 2.83
Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci U S A (1991) 2.67
The intermediate endpoint effect in logistic and probit regression. Clin Trials (2007) 2.67
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol (1990) 2.65
Poliovirus neutralization epitopes: analysis and localization with neutralizing monoclonal antibodies. J Virol (1982) 2.63
Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies. J Virol (1983) 2.24
Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci U S A (1999) 2.21
Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization. J Virol (1983) 2.18
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Carboxy-terminal analysis of poliovirus proteins: termination of poliovirus RNA translation and location of unique poliovirus polyprotein cleavage sites. J Virol (1982) 2.11
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis (2000) 2.10
Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother (1993) 2.10
Performance characteristics of a whole-body PET scanner. J Nucl Med (1994) 2.08
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem (1994) 2.07
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol (1991) 2.05
Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J Biol Chem (1992) 2.04
Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis (1998) 1.89
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med (2000) 1.88
Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses (1997) 1.84
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol (1995) 1.75
Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol (2001) 1.72
The cost of treating heart valve related complications. J Heart Valve Dis (1996) 1.71
The incidence of patent foramen ovale in 1,000 consecutive patients. A contrast transesophageal echocardiography study. Chest (1995) 1.69
Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem (1994) 1.68
Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade. J Virol (1986) 1.68
Role of posterior parietal cortex in the recalibration of visually guided reaching. Nature (1996) 1.66
Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest (1999) 1.64
X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293)--an initial glance of the viral DNA binding platform. J Mol Biol (2000) 1.63
[18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR Am J Neuroradiol (1993) 1.62
Identification of a poliovirus neutralization epitope through use of neutralizing antiserum raised against a purified viral structural protein. Virology (1983) 1.61
Recombinants of Mahoney and Sabin strain poliovirus type 1: analysis of in vitro phenotypic markers and evidence that resistance to guanidine maps in the nonstructural proteins. Virology (1984) 1.60
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA (1998) 1.59
Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology (1997) 1.56
Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science (1987) 1.56
Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis (2008) 1.55
Temporal lobe hypometabolism on PET: predictor of seizure control after temporal lobectomy. Neurology (1993) 1.54
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J Med Chem (1993) 1.54
Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob Agents Chemother (1994) 1.53
Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology (1993) 1.53
Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med (1987) 1.51
The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol (1994) 1.48
A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res (1994) 1.47
Tracheal collapse in two cats. J Am Vet Med Assoc (1985) 1.45
Alterations in the functional anatomy of working memory in adult attention deficit hyperactivity disorder. Am J Psychiatry (2000) 1.45
A Schwann cell mitogen accompanying regeneration of motor neurons. Nature (1997) 1.44
PGY1. J Am Coll Dent (1996) 1.40
Child abuse in the dental operatory. N Y State Dent J (1989) 1.39
Management of respiratory emergencies in small animals. Vet Clin North Am (1972) 1.39
Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother (1992) 1.39
Plenty of blame to go around. N Y State Dent J (1998) 1.38
HIV and multidrug resistance. Nature (1993) 1.31
Compensatory recruitment of neural resources during overt rehearsal of word lists in Alzheimer's disease. Neuropsychology (1998) 1.31
A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity. J Virol Methods (1988) 1.31
Doppler echocardiographic analysis of left ventricular filling in treated hypertensive patients. J Am Coll Cardiol (1987) 1.30
Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med (1994) 1.30
4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem (2000) 1.30
Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycins: competitive interaction at the template.primer site. Mol Pharmacol (1990) 1.30